Making the undruggable druggable
Unlocking challenging drug targets for the development of next-generation therapeutics
Selected Collaborations
It all starts with the drug target.
The majority of drug targets are so-called membrane proteins, and these are inherently unstable and challenging to investigate. Or so they were, until now.
Our proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies or small molecule drugs. Through our in-house and partnered pipelines, we drive the discovery of novel drugs.
Pushing drug development forward together
We work with top-tier pharma and biotech partners to unlock drug targets for drug development programs.
Pipeline
We are driving forward drug development in our partnered as well as internal pipelines.
News
Salipro Biotech is heading to Swiss Biotech Day 2026!
2026-04-14
We are participating in Swiss Biotech Day, taking place in Basel from May 4-5 where our Business Development Manager, Lorena Galán Acosta, will be attending in person.
We look forward to connecting with current and future partners in Switzerland to discuss how the Salipro® platform can unlock drug discovery for complex membrane protein targets, including GPCRs, ion channels, and transporters.
If you’d like to meet in Basel, feel free to reach out via the partnering platform to schedule a meeting. Let’s discuss how the Salipro® platform can drive the development of next-generation therapeutics!
Multi-Target Collaboration Agreement with Global Top 5 Pharma Company
2026-04-02
Salipro has entered into a multi-target collaboration agreement with a global Top 5 pharmaceutical company in the USA.
This partnership leverages Salipro Biotech’s expertise and proprietary technology (Salipro®) to stabilise challenging drug targets including GPCRs, ion channels and transporters, making them accessible for the development of next-generation therapeutics.
Stay tuned for more updates as we continue to push the boundaries of drug discovery!
Press Release: Salipro Biotech Expands Global Intellectual Property Estate with Key U.S. Patent Grant
2026-02-17
New U.S. patent secures long term protection for the Salipro® platform technologies, extending exclusivity until 2042 and reinforcing the company’s position as a premier partner for drug discovery against challenging drug targets.
Stockholm, Sweden, February 17, 2026 — Salipro Biotech AB, a pioneering biotech company enabling drug discovery against challenging membrane protein targets, today announced that the United States Patent and Trademark Office has granted U.S. Patent No. 12,383,501, entitled “Production of Salipro Particles”. The patent extends the company’s IP protection for its Salipro® platform technologies into June 2042.
Salipro Biotech’s global patent estate now includes over 60 granted patents spanning the U.S., EU, China, Japan, Australia, Singapore, and other major life‑science markets. Together, these patents protect the core elements of the Salipro® technology, which stabilizes membrane proteins in their native lipid environment to deliver high-quality functional targets for small‑molecule drug discovery, biologics development as well as structure‑based drug design.
Find the full press release here.